Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00888-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Thaila Fernanda Dos Reis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Antifungal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
Aspergillus fumigatus is the primary etiological agent of aspergillosis. Here, we show that the host defense peptide mimetic brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of A. fumigatus . BRI + IBX can inhibit the growth of A. fumigatus voriconazole- and caspofungin-resistant clinical isolates. BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against viruses, bacteria, and fungi. In vitro , combination of BRI + IBX plays a fungicidal role, increases the fungal cell permeability, decreases the fungal survival in the presence of A549 epithelial cells, and appears as a promising antifungal therapeutic alternative against A. fumigatus . IMPORTANCE Invasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. Aspergillus fumigatus causes a series of distinct invasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. A. fumigatus causes a spectrum of distinct clinical entities named aspergillosis, which the most severe form is the invasive pulmonary aspergillosis. There are few therapeutic options for treating aspergillosis and searching for new antifungal agents against this disease is very important. Here, we present brilacidin (BRI) as a synergizer o fibrexafungerp (IBX) against A. fumigatus . BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against bacteria and viruses. We propose the combination of BRI and IBX as a new antifungal combinatorial treatment against aspergillosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
- National Institute of Science and Technology in Human Pathogenic Fungi, São Paulo, Brazil.
ORCID-Profile: Thaila Fernanda Dos Reis, Gustavo H Goldman
Förderung
- NIAID NIH HHS
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Dos Reis, T. F., Diehl, C., Pinzan, C. F., de Castro, P. A., & Goldman, G. H. (2024). Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00888-24
Vancouver
Dos Reis TF, Diehl C, Pinzan CF, de Castro PA, Goldman GH. Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00888-24
BibTeX
@article{DosReis2024,
author = {Dos Reis, Thaila Fernanda and Diehl, Camila and Pinzan, Camila Figueiredo and de Castro, Patrícia Alves and Goldman, Gustavo H},
title = {Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00888-24}
}
EUVIMED